Literature DB >> 26056544

B-type natriuretic peptide in predicting the severity of community-acquired pneumonia.

Jing Li1, Huan Ye1, Li Zhao1.   

Abstract

BACKGROUND: Although pneumonia severity index (PSI) is widely used to evaluate the severity of community-acquired pneumonia (CAP), the calculation of PSI is very complicated. The present study aimed to evaluate the role of B-type natriuretic peptide (BNP) in predicting the severity of CAP.
METHODS: For 202 patients with CAP admitted to the emergency department, BNP levels, cardiac load indexes, inflammatory indexes including C-reactive protein (CRP), white blood cell count (WBC), and PSI were detected. The correlation between the indexes and PSI was investigated. BNP levels for survivor and non-survivor groups were compared, and a receiver operating characteristic (ROC) curve analysis was performed on the BNP levels versus PSI.
RESULTS: The BNP levels increased with CAP severity (r=0.782, P<0.001). The BNP levels of the high-risk group (PSI classes IV and V) were significantly higher than those of the low-risk group (PSI classes I-III) (P<0.001). The BNP levels were significantly higher in the non-survivor group than in the survivor group (P<0.001). In addition, there were positive correlations between BNP levels and PSI scores (r=0.782, P<0.001). The BNP level was highly accurate in predicting the severity of CAP (AUC=0.952). The optimal cut-off point of BNP level for distinguishing high-risk patients from low-risk ones was 125.0 pg/mL, with a sensitivity of 0.891 and a specificity of 0.946. Moreover, BNP level was accurate in predicting mortality (AUC=0.823). Its optimal cut-off point for predicting death was 299.0 pg/mL, with a sensitivity of 0.675 and a specificity of 0.816. Its negative predictive cut-off value was 0.926, and the positive predictive cut-off value was 0.426.
CONCLUSION: BNP level is positively correlated with the severity of CAP, and may be used as a biomarker for evaluating the severity of CAP.

Entities:  

Keywords:  B-type natriuretic peptide; Biomarker; Community-acquired pneumonia; Disease severity assessment; Emergency; Pneumonia severity index

Year:  2015        PMID: 26056544      PMCID: PMC4458473          DOI: 10.5847/wjem.j.1920-8642.2015.02.008

Source DB:  PubMed          Journal:  World J Emerg Med        ISSN: 1920-8642


  23 in total

1.  B-type natriuretic peptide for risk stratification in community-acquired pneumonia.

Authors:  C Mueller; K Laule-Kilian; A Scholer; A P Perruchoud
Journal:  J Intern Med       Date:  2005-10       Impact factor: 8.989

2.  Natriuretic peptides--relevance in cardiovascular disease.

Authors:  B M Cheung; C R Kumana
Journal:  JAMA       Date:  1998-12-16       Impact factor: 56.272

3.  Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure.

Authors:  T Langenickel; I Pagel; K Höhnel; R Dietz; R Willenbrock
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-05       Impact factor: 4.733

4.  Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure.

Authors:  M S Weinfeld; G M Chertow; L W Stevenson
Journal:  Am Heart J       Date:  1999-08       Impact factor: 4.749

5.  Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea.

Authors:  Christian Mueller; Kirsten Laule-Kilian; Christian Schindler; Theresia Klima; Barbara Frana; Daniel Rodriguez; André Scholer; Michael Christ; André P Perruchoud
Journal:  Arch Intern Med       Date:  2006-05-22

6.  Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis.

Authors:  Martina Brueckmann; Guenter Huhle; Siegfried Lang; Karl K Haase; Thomas Bertsch; Christel Weiss; Jens J Kaden; Christian Putensen; Martin Borggrefe; Ursula Hoffmann
Journal:  Circulation       Date:  2005-07-18       Impact factor: 29.690

Review 7.  Natriuretic peptides, respiratory disease, and the right heart.

Authors:  Lok Bin Yap; Dev Mukerjee; Peter M Timms; Houman Ashrafian; John Gerard Coghlan
Journal:  Chest       Date:  2004-10       Impact factor: 9.410

8.  Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes.

Authors:  Kou-ichi Tomaru Ki; Masashi Arai; Tomoyuki Yokoyama; Yasushi Aihara; Ken-ichi Sekiguchi Ki; Toru Tanaka; Ryozo Nagai; Masahiko Kurabayashi
Journal:  J Mol Cell Cardiol       Date:  2002-06       Impact factor: 5.000

9.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.

Authors:  Christian Mueller; André Scholer; Kirsten Laule-Kilian; Benedict Martina; Christian Schindler; Peter Buser; Matthias Pfisterer; André P Perruchoud
Journal:  N Engl J Med       Date:  2004-02-12       Impact factor: 91.245

10.  Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study.

Authors:  Nils G Morgenthaler; Joachim Struck; Mirjam Christ-Crain; Andreas Bergmann; Beat Müller
Journal:  Crit Care       Date:  2004-12-17       Impact factor: 9.097

View more
  3 in total

1.  Validation of a B-type natriuretic peptide as a prognostic marker in pneumonia patients: a prospective cohort study.

Authors:  Daisuke Usuda; Ryusho Sangen; Yu Hashimoto; Emiri Muranaka; Yoshitsugu Iinuma; Tsugiyasu Kanda
Journal:  BMJ Open       Date:  2016-02-23       Impact factor: 2.692

2.  Do N-terminal pro-brain natriuretic peptide levels determine the prognosis of community acquired pneumonia?

Authors:  Evrim Eylem Akpınar; Derya Hoşgün; Serdar Akpınar; Can Ateş; Ayşe Baha; Esen Sayın Gülensoy; Nalan Ogan
Journal:  J Bras Pneumol       Date:  2019-08-12       Impact factor: 2.624

3.  Expanded A-DROP Score: A New Scoring System for the Prediction of Mortality in Hospitalized Patients with Community-acquired Pneumonia.

Authors:  June Hong Ahn; Eun Young Choi
Journal:  Sci Rep       Date:  2018-10-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.